Why AstraZeneca’s Truqap win could force a new testing era in prostate cancer
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.
Medical Devices & Diagnostics
Pharma & Biotech
Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations
Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?